Combining Antibody-drug Conjugates with Immunotherapy in Solid Tumors: Current Landscape and Future Perspectives

In the last few decades, the development of a multiplicity of innovative anticancer agents promoted great improvements in the outcome of cancer patients[1]. Among these, stands out the role of antibody-drug conjugates (ADCs), designed to selectively deliver highly potent cytotoxic agents to target cancer cells, thus improving efficacy and limiting toxicities. ADCs are composed of three main components: an antibody, a linker, and a payload. Their mechanism of action can be summarized as follows: upon the binding of the antibody (Ab) to the antigen expressed on the surface of target cell, the ADC is internalized and processed to release the payload, which exerts its effects leading to cell death[2].

Source: Cancer Treatment Reviews - April 16, 2022 Category: Cancer & Oncology Authors: Eleonora Nicol ò, Federica Giugliano, Liliana Ascione, Paolo Tarantino, Chiara Corti, Sara M. Tolaney, Massimo Cristofanilli, Giuseppe Curigliano Source Type: research